PMID- 29487007
OWN - NLM
STAT- MEDLINE
DCOM- 20180904
LR  - 20221207
IS  - 1618-0631 (Electronic)
IS  - 0344-0338 (Linking)
VI  - 214
IP  - 3
DP  - 2018 Mar
TI  - MiR-21-5p, miR-34a, and human telomerase RNA component as surrogate markers for 
      cervical cancer progression.
PG  - 374-379
LID - S0344-0338(17)31013-0 [pii]
LID - 10.1016/j.prp.2018.01.001 [doi]
AB  - OBJECTIVE: This study aimed to demonstrate the predictive value of miR-21-5p, 
      miR-34a, and human telomerase RNA component (hTERC) in cervical cancer (CC) 
      development and evaluated their potential possibility for future clinical 
      applications. METHODS: Specimens were collected from the normal cervix, cervical 
      intraepithelial neoplasia (CIN) I, CIN II/III, cervical squamous cell carcinoma. 
      Cytological evaluations and histopathologic examinations were conducted in all 
      subjects, along with the assessment of human papillomavirus (HPV) DNA. The 
      expression levels of the miR-21-5p and miR-34a were detected by RT-PCR. hTERC 
      amplification was detected by dual-color interphase fluorescence in situ 
      hybridization (FISH). Then miRNA, hTERC expressions were compared with the 
      cytological and histologic examination. RESULTS: Compared to that in the benign 
      samples, the expression of miR-21-5p and miR-34a in abnormal samples was 
      significantly upregulated and downregulated, gradually corresponding to the 
      severity of cervical lesions (P < 0.05). There was a trend toward an increasing 
      amplification of hTERC with the increasing severity of cervical lesions. 
      miR-21-5p and miR-34a expression, and hTERC amplification were more specific than 
      HPV positivity in differentiating low-grade cervical disorders from high-grade 
      ones (P < 0.05). CONCLUSIONS: MiR-21-5p upregulation, miR-34a downregulation, and 
      hTERC amplification were associated with the aggressive progression of CC, which 
      suggests that miR-21-5p, miR-34a and hTERC might serve as surrogate markers for 
      CC progression and potential molecular targets for blockage of the development of 
      CC.
CI  - Copyright (c) 2018 Elsevier GmbH. All rights reserved.
FAU - Zhu, Yue
AU  - Zhu Y
AD  - Department of Gynaecology and Obstetrics, Yiwu Central Hospital, Yiwu, Zhejiang 
      322000, China.
FAU - Han, Ying
AU  - Han Y
AD  - Department of Gynecology, Gongli Hospital of Pudong New District of Shanghai 
      City, Shanghai 200135, China.
FAU - Tian, Tian
AU  - Tian T
AD  - Department of Gynecology, Gongli Hospital of Pudong New District of Shanghai 
      City, Shanghai 200135, China.
FAU - Su, Peihong
AU  - Su P
AD  - Department of Gynecology, Gongli Hospital of Pudong New District of Shanghai 
      City, Shanghai 200135, China.
FAU - Jin, Guan
AU  - Jin G
AD  - Department of Gynecology, Gongli Hospital of Pudong New District of Shanghai 
      City, Shanghai 200135, China.
FAU - Chen, Juan
AU  - Chen J
AD  - Department of Gynecology, Gongli Hospital of Pudong New District of Shanghai 
      City, Shanghai 200135, China. Electronic address: huchuanyi2001@163.com.
FAU - Cao, Yungui
AU  - Cao Y
AD  - Department of Gynecology, Jiading District Maternal and Child Health Hospital, 
      Shanghai 201800, China. Electronic address: cygui@126.com.
LA  - eng
PT  - Journal Article
DEP - 20180109
PL  - Germany
TA  - Pathol Res Pract
JT  - Pathology, research and practice
JID - 7806109
RN  - 0 (DNA, Viral)
RN  - 0 (MIRN21 microRNA, human)
RN  - 0 (MIRN34 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (telomerase RNA)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adult
MH  - DNA, Viral/genetics
MH  - Disease Progression
MH  - Female
MH  - Gene Amplification/genetics
MH  - Humans
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Neoplastic Processes
MH  - Papillomavirus Infections/virology
MH  - RNA/*genetics
MH  - Telomerase/*genetics
MH  - Uterine Cervical Dysplasia/genetics/pathology/virology
MH  - Uterine Cervical Neoplasms/*genetics/*pathology/virology
OTO - NOTNLM
OT  - Biomarker
OT  - Cervical cancer progression
OT  - hTERC
OT  - miR-34a
OT  - miRNA-21-5p
EDAT- 2018/03/01 06:00
MHDA- 2018/09/05 06:00
CRDT- 2018/03/01 06:00
PHST- 2017/10/09 00:00 [received]
PHST- 2017/12/15 00:00 [revised]
PHST- 2018/01/05 00:00 [accepted]
PHST- 2018/03/01 06:00 [pubmed]
PHST- 2018/09/05 06:00 [medline]
PHST- 2018/03/01 06:00 [entrez]
AID - S0344-0338(17)31013-0 [pii]
AID - 10.1016/j.prp.2018.01.001 [doi]
PST - ppublish
SO  - Pathol Res Pract. 2018 Mar;214(3):374-379. doi: 10.1016/j.prp.2018.01.001. Epub 
      2018 Jan 9.